{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.ai-analytics.org/api/v1/entity/PODD/timeline","_source":{"data_provider":"AI Analytics","data_provider_url":"https://api.ai-analytics.org","license":"https://api.ai-analytics.org/license","usage_info":"https://api.ai-analytics.org/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-22T18:18:53.067Z","methodology_url":"https://api.ai-analytics.org/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":8886,"canonical_name":"INSULET CORP","cik":"0001145197","uei":null,"lei":null,"duns":null,"ticker":"PODD"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","open.payments","dol.form5500","hud.housing","irs.bmf"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":35,"fda":3,"clinical":7,"open":1},"count":46,"timeline":[{"ts":"2026-07-02","kind":"sec.filing","form_type":"3","title":"3 — INSULET CORP — 2026-07-02","url_slug":"/sec/cik-0001145197/3/0001145197-26-000154","accession_number":"0001145197-26-000154","importance":30},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — INSULET CORP — 2026-07-02","url_slug":"/sec/cik-0001145197/4/0001145197-26-000153","accession_number":"0001145197-26-000153","importance":30},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — INSULET CORP — 2026-07-02","url_slug":"/sec/cik-0001145197/4/0001145197-26-000155","accession_number":"0001145197-26-000155","importance":30},{"ts":"2026-07-01","kind":"sec.insider.a","reporter":"MAZELSKY JONATHAN JAY","title":null,"shares":1355,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-30","kind":"sec.insider.a","reporter":"Huffines Robert Luther","title":null,"shares":144,"price_per_share":159.79,"usd_value":23010,"security_title":"Common Stock","importance":15.02300976},{"ts":"2026-06-30","kind":"sec.insider.a","reporter":"Huffines Robert Luther","title":null,"shares":151,"price_per_share":152.25,"usd_value":22990,"security_title":"Common Stock","importance":15.02298975},{"ts":"2026-06-25","kind":"sec.filing","form_type":"8-K","title":"8-K — INSULET CORP — 2026-06-25","url_slug":"/sec/cik-0001145197/8-k/0001145197-26-000148","accession_number":"0001145197-26-000148","importance":35},{"ts":"2026-06-04","kind":"sec.filing","form_type":"4","title":"4 — INSULET CORP — 2026-06-04","url_slug":"/sec/cik-0001145197/4/0001145197-26-000142","accession_number":"0001145197-26-000142","importance":30},{"ts":"2026-06-04","kind":"sec.filing","form_type":"4","title":"4 — INSULET CORP — 2026-06-04","url_slug":"/sec/cik-0001145197/4/0001145197-26-000143","accession_number":"0001145197-26-000143","importance":30},{"ts":"2026-06-03","kind":"sec.insider.p","reporter":"WEATHERMAN ELIZABETH H","title":null,"shares":3450,"price_per_share":144.2,"usd_value":497490,"security_title":"Common Stock","importance":50.49749},{"ts":"2026-06-03","kind":"sec.insider.p","reporter":"STONESIFER TIMOTHY C.","title":null,"shares":2790,"price_per_share":143.51,"usd_value":400393,"security_title":"Common Stock","importance":50.4003929},{"ts":"2026-06-03","kind":"sec.form144","reporter":"BORIO LUCIANA","title":"Director","shares":418,"usd_value":59885,"security_title":"Common","approx_sale_date":"2026-06-03","accession_number":"0001959173-26-004306","importance":40.011976954},{"ts":"2026-06-03","kind":"sec.insider.s","reporter":"BORIO LUCIANA","title":null,"shares":418,"price_per_share":143.27,"usd_value":59887,"security_title":"Common Stock","importance":35.05988686},{"ts":"2026-06-03","kind":"sec.filing","form_type":"144","title":"144 — INSULET CORP — 2026-06-03","url_slug":"/sec/cik-0001145197/144/0001959173-26-004306","accession_number":"0001959173-26-004306","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"4","title":"4 — INSULET CORP — 2026-06-03","url_slug":"/sec/cik-0001145197/4/0001145197-26-000138","accession_number":"0001145197-26-000138","importance":30},{"ts":"2026-05-21","kind":"sec.filing","form_type":"8-K","title":"8-K — INSULET CORP — 2026-05-21","url_slug":"/sec/cik-0001145197/8-k/0001145197-26-000121","accession_number":"0001145197-26-000121","importance":35},{"ts":"2026-05-21","kind":"sec.filing","form_type":"4","title":"4 — INSULET CORP — 2026-05-21","url_slug":"/sec/cik-0001145197/4/0001145197-26-000122","accession_number":"0001145197-26-000122","importance":30},{"ts":"2026-05-21","kind":"sec.filing","form_type":"4","title":"4 — INSULET CORP — 2026-05-21","url_slug":"/sec/cik-0001145197/4/0001145197-26-000123","accession_number":"0001145197-26-000123","importance":30},{"ts":"2026-05-21","kind":"sec.filing","form_type":"4","title":"4 — INSULET CORP — 2026-05-21","url_slug":"/sec/cik-0001145197/4/0001145197-26-000124","accession_number":"0001145197-26-000124","importance":30},{"ts":"2026-05-21","kind":"sec.filing","form_type":"4","title":"4 — INSULET CORP — 2026-05-21","url_slug":"/sec/cik-0001145197/4/0001145197-26-000125","accession_number":"0001145197-26-000125","importance":30},{"ts":"2026-05-21","kind":"sec.filing","form_type":"4","title":"4 — INSULET CORP — 2026-05-21","url_slug":"/sec/cik-0001145197/4/0001145197-26-000126","accession_number":"0001145197-26-000126","importance":30},{"ts":"2026-05-21","kind":"sec.filing","form_type":"4","title":"4 — INSULET CORP — 2026-05-21","url_slug":"/sec/cik-0001145197/4/0001145197-26-000127","accession_number":"0001145197-26-000127","importance":30},{"ts":"2026-05-21","kind":"sec.filing","form_type":"4","title":"4 — INSULET CORP — 2026-05-21","url_slug":"/sec/cik-0001145197/4/0001145197-26-000128","accession_number":"0001145197-26-000128","importance":30},{"ts":"2026-05-21","kind":"sec.filing","form_type":"4","title":"4 — INSULET CORP — 2026-05-21","url_slug":"/sec/cik-0001145197/4/0001145197-26-000129","accession_number":"0001145197-26-000129","importance":30},{"ts":"2026-05-20","kind":"fda.recall","reporter":"Insulet Corporation","title":"Class I","security_title":"Omnipod 5 Pods. Includes the below Model/REF Numbers:     1. POD-OMNI-I1-6720.    2. POD-OMNI-I1-6220.     3. OMNI-I1-6729 (10-Pack), OMNI-I1-6720 (Single Pod).     4. OMNI-I1-6220.     5. OMNI-I1-6720.     6. BLE-H1-529 (10-Pack), BLE-H1-520 (Single Pod).","excerpt":"External soft cannula damage during manufacturing that results in insulin leaking around the Pod instead of being delivered to the user regardless of basal or bolus delivery. The primary failure mode is pump under-delivery due to loss of insulin to an external leak. If insulin is not delivered properly, users may experience high blood glucose levels due to under-delivery of insulin. In the most severe cases, prolonged and persistent high blood glucose levels can lead to diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar syndrome (HHS), or even death.","accession_number":"Z-2603-2026","status":"Ongoing","product_type":"device","importance":100},{"ts":"2026-05-20","kind":"fda.recall","reporter":"Insulet Corporation","title":"Class I","security_title":"Omnipod DASH Pod. Includes the below Model/REF Numbers:     1. POD-BLE-I1-525 (5-Pack), POD-BLE-I1-520 (Single Pod).     2. POD-BLE-I1-529 (10-Pack), POD-BLE-I1-520 (Single Pod).     3. BLE-I1-529 (10-Pack), BLE-I1-520 (Single Pod).     4. BLE-C1-529 (10-Pack), BLE-C1-520 (Single Pod).","excerpt":"External soft cannula damage during manufacturing that results in insulin leaking around the Pod instead of being delivered to the user regardless of basal or bolus delivery. The primary failure mode is pump under-delivery due to loss of insulin to an external leak. If insulin is not delivered properly, users may experience high blood glucose levels due to under-delivery of insulin. In the most severe cases, prolonged and persistent high blood glucose levels can lead to diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar syndrome (HHS), or even death.","accession_number":"Z-2604-2026","status":"Ongoing","product_type":"device","importance":100},{"ts":"2026-05-20","kind":"fda.recall","reporter":"Insulet Corporation","title":"Class I","security_title":"Omnipod (Eros) Pod. Includes the below Model/REF Numbers:     1. POD-ZXP425 (10 Pack), POD- ZXP420 (Single Pod).     2. ZXR425 (10-Pack), ZXR420 (Single Pod).     3. ZXP425 (10 Pack), ZXP420 (Single Pod).","excerpt":"External soft cannula damage during manufacturing that results in insulin leaking around the Pod instead of being delivered to the user regardless of basal or bolus delivery. The primary failure mode is pump under-delivery due to loss of insulin to an external leak. If insulin is not delivered properly, users may experience high blood glucose levels due to under-delivery of insulin. In the most severe cases, prolonged and persistent high blood glucose levels can lead to diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar syndrome (HHS), or even death.","accession_number":"Z-2605-2026","status":"Ongoing","product_type":"device","importance":100},{"ts":"2026-05-20","kind":"sec.insider.a","reporter":"BORIO LUCIANA","title":null,"shares":1660,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-20","kind":"sec.insider.a","reporter":"Frederick Wayne A.I.","title":null,"shares":1660,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-20","kind":"sec.insider.a","reporter":"Huffines Robert Luther","title":null,"shares":1660,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-20","kind":"sec.insider.a","reporter":"Hopfield Jessica","title":null,"shares":1660,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-20","kind":"sec.insider.a","reporter":"MINOGUE MICHAEL R","title":null,"shares":1660,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-20","kind":"sec.insider.a","reporter":"Scannell Timothy J","title":null,"shares":1660,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-20","kind":"sec.insider.a","reporter":"STONESIFER TIMOTHY C.","title":null,"shares":1660,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-20","kind":"sec.insider.a","reporter":"WEATHERMAN ELIZABETH H","title":null,"shares":1660,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-18","kind":"clinical.trial","reporter":"Insulet Corporation","title":"Evaluating Glucose Control Using a Next-Generation AID Algorithm in Adults With T1D","security_title":"NA","status":"NOT_YET_RECRUITING","accession_number":"NCT07593625","excerpt":"[\"Type 1 Diabetes\",\"Type 1 Diabetes Mellitus\",\"Diabetes (DM)\"]","importance":25},{"ts":"2026-05-15","kind":"sec.filing","form_type":"4","title":"4 — INSULET CORP — 2026-05-15","url_slug":"/sec/cik-0001145197/4/0001145197-26-000105","accession_number":"0001145197-26-000105","importance":30},{"ts":"2026-05-14","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — INSULET CORP — 2026-05-14","url_slug":"/sec/cik-0001145197/schedule-13g-a/0001422848-26-000059","accession_number":"0001422848-26-000059","importance":30},{"ts":"2026-05-13","kind":"sec.insider.f","reporter":"McEvoy Ashley","title":"President and CEO","shares":1411,"price_per_share":148.84,"usd_value":210013,"security_title":"Common Stock","importance":15.21001324},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"Insulet Corporation","title":"Omnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B)","security_title":null,"status":"RECRUITING","accession_number":"NCT07317102","excerpt":"[\"Diabetes\",\"Type 1 Diabetes\",\"Diabetes Mellitus\"]","importance":25},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"Insulet Corporation","title":"An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes","security_title":"NA","status":"COMPLETED","accession_number":"NCT07276776","excerpt":"[\"Type 2 Diabetes Mellitus\"]","importance":25},{"ts":"2026-05-04","kind":"clinical.trial","reporter":"Insulet Corporation","title":"French Prospective Multicentric Study in Real World","security_title":null,"status":"RECRUITING","accession_number":"NCT07039942","excerpt":"[\"Diabetes\",\"Diabetes Mellitus\",\"Type 1 Diabetes\"]","importance":25},{"ts":"2026-05-04","kind":"clinical.trial","reporter":"Insulet Corporation","title":"Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes","security_title":null,"status":"RECRUITING","accession_number":"NCT06144554","excerpt":"[\"Type 1 Diabetes\"]","importance":25},{"ts":"2026-04-14","kind":"clinical.trial","reporter":"Insulet Corporation","title":"Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes","security_title":"NA","status":"NOT_YET_RECRUITING","accession_number":"NCT07521475","excerpt":"[\"Type 2 Diabetes Mellitus\"]","importance":25},{"ts":"2026-04-14","kind":"clinical.trial","reporter":"Insulet Corporation","title":"Omnipod® 5 With Libre 2 vs. MDI for Type 1 Diabetes in Children and Adults","security_title":"NA","status":"COMPLETED","accession_number":"NCT05923827","excerpt":"[\"Diabetes Mellitus, Type 1\"]","importance":25},{"ts":"2024-12-31","kind":"open.payments","reporter":"Insulet Corporation","title":"$1391059.0 to 5858 physicians (2024–2024)","security_title":"manufacturer","excerpt":"Omnipod","accession_number":"2024","usd_value":1391059,"importance":70}]}